Please note that this content was created in 2018. In the time since this material was posted, there may have been additional developments, advancements, and/or more current publications in this field.
AMP Education is constantly updating our educational offerings, and will remove or replace content that is no longer accurate. Please be sure to use the search function to find related or updated material available in our catalogue at educate.amp.org. The Training and Education Committee works with AMP Education Programs to bring you the most up-to-date and cutting-edge information on molecular pathology research, applications, and training.
This is a recording of a session from the AMP 2018 Annual Meeting & Expo. Purchase the entire AMP Annual Meeting & Expo 2018 Recordings for a significant discount!
This session is dedicated to presentations of unique and state-of-the-art molecular methods for the detection and quantitation of infectious disease organisms in patient samples.
Validation of the Karius Microbial Cell-free DNA Sequencing Test for Infectious Disease
Timothy A. Blauwkamp, PhD, Karius, Inc., Redwood City, CA, USA
Objectives:
- Describe the unique advantages of using microbial cell-free DNA sequencing to identify infectious diseases.
- Discuss results from analytical and clinical validations of quantitative microbial cfDNA sequencing tests.
- Outline the new integrative technology called "Universal Digital High Resolution Melt" which unites the advantages of digital PCR, high resolution melting of DNA, and machine learning to detect infectious microbes.
Duration: 0.50 hr
Recording Date: November 1, 2018
Last day to purchase: December
31, 2021
Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
